Prescription medicine
Aprepitant Brand names: Emend, Aponvie, Cinvanti
Aprepitant (Emend) is a prescription medicine with an FDA approval on record since 2003. FDA's NDC Directory lists it from 5 generic labelers, and pharmacies paid $46.42 per aprepitant 40 mg capsule in the October 7, 2026 NADAC survey.
- Generic listed
- A presentation discontinued
Check it at the source: the aprepitant FDA label on DailyMed (effective July 5, 2024, Merck Sharp & Dohme LLC); the NDA 21549 record on Drugs@FDA; every aprepitant label on DailyMed.
Highlights of the record
FDA label of July 5, 2024; NDC Directory, Drugs@FDA and Orange Book, October 8, 2026; NADAC October 7, 2026
Used for
From the label: indications and usageEMEND ® for oral suspension, in combination with other antiemetic agents, is indicated in patients 6 months of age and older for the prevention of: acute and delayed nausea and vomiting associated with initial and repeat courses of highly emetogenic cancer chemotherapy (HEC) including high-dose cisplatin.
Forms and strengths
- 40 mg
- 80 mg
- 125 mg
- 32 mg/4.4ml
- 130 mg/18ml
Capsule; kit; emulsion; powder for suspension; injection (emulsion).
On the market
- Earliest approval on file
- March 26, 2003 Emend, Msd; Drugs@FDA’s file, where older or withdrawn approvals can be missing
- Generic approvals
- 4 first September 24, 2012; 3 with a marketed status in Drugs@FDA
- Labelers listed (NDC)
- 7 of which 5 under generic applications, 2 under brand applications, repackagers included
- Last listed patent
- September 26, 2027 Emend capsules; not a generic launch date
Supply and safety
- Pharmacy cost (NADAC)
- $46.42 per capsule Aprepitant 40 mg capsule
- Shortage (FDA)
- None current 1 past records
- Recalls by its makers (FDA)
- 3 since 2018 0 Class I among all firms' recalls; latest December 12, 2025
- FAERS reports
- 18,353 through July 30, 2026
What is aprepitant used for?
From the label: indications and usageEMEND ® for oral suspension, in combination with other antiemetic agents, is indicated in patients 6 months of age and older for the prevention of: acute and delayed nausea and vomiting associated with initial and repeat courses of highly emetogenic cancer chemotherapy (HEC) including high-dose cisplatin. nausea and vomiting associated with initial and repeat courses of moderately emetogenic cancer chemotherapy (MEC). […]
Conditions named in the indications of aprepitant's FDA labels, with every medicine labeled for each:
From other aprepitant labelsNausea and vomiting: Nausea and Vomiting (PONV) Aprepitant capsules are indicated in adults for the prevention of postoperative nausea and vomiting.
FDA pharmacologic class: Substance P/Neurokinin-1 Receptor Antagonist.
Source: FDA drug label (EMEND), NDA021549 (Msd), as published by Merck Sharp & Dohme LLC, effective July 5, 2024 (SPL set 696f9e80-9cae-403b-de9e-078343ce4713), via openFDA; the full label on DailyMed
Is there a generic for aprepitant (Emend)?
The FDA approved the first generic aprepitant on September 24, 2012. 4 generic applications are approved; 3 of them carry a current (not discontinued) marketing status in Drugs@FDA; that status is not evidence that the generic is on sale. Drugs@FDA also holds 1 tentative approval: the FDA found the generic approvable, but patents or exclusivity keep it from final approval for now.
FDA's NDC Directory lists aprepitant from 5 labelers under a generic (ANDA) application and from 2 brand labelers. A listing means the company has registered the product for sale; it does not show that every pharmacy stocks it.
The Orange Book lists 1 patent for Emend capsules, the last expiring on September 26, 2027; a patent listed only for Aponvie injection runs to September 18, 2035. A patent or exclusivity date is not the date a generic goes on sale: court cases and settlements move it either way.
- 2003 earliest approval on file
- 2012 first generic approved
- 2027 last listed patent
- red ticks recalls
Source: Drugs@FDA, FDA NDC Directory and the Orange Book (openFDA bulk files, October 8, 2026)
What do pharmacies pay for aprepitant (Emend)?
In CMS's NADAC survey of October 7, 2026, pharmacies paid $46.42 per Aprepitant 40 mg capsule, about the same as a year earlier. The chart's scale runs from the lowest to the highest price shown, not from zero. NADAC is what retail pharmacies paid their wholesalers, per unit, in CMS's monthly survey; what a patient pays depends on insurance and the pharmacy.
- Aprepitant 40 mg capsule (generic)
- Emend 125 mg powder packet (brand)
| Strength and form | Brand or generic | Pharmacy cost | 30 tablets, or one pen or vial | 12-month change |
|---|---|---|---|---|
| Aprepitant 125 mg capsule | Generic | $114.04 per capsule | $3,421.32 | -36% |
| Aprepitant 125-80-80 mg pack | Generic | $85.02 per unit | n/a | -24% |
| Aprepitant 40 mg capsule | Generic | $46.42 per capsule | $1,392.62 | no change |
| Aprepitant 80 mg capsule | Generic | $76.35 per capsule | $2,290.57 | -12% |
| Emend 125 mg powder packet | Brand | $327.38 per packet | n/a | +0.2% |
Source: CMS National Average Drug Acquisition Cost (NADAC) survey, October 7, 2026: what retail pharmacies paid per unit; not a counter price
Is aprepitant in shortage?
No aprepitant presentation is listed as in shortage in the FDA Drug Shortage Database (read October 8, 2026); its 1 record is all marked to be discontinued, the latest updated April 8, 2026. ASHP keeps a separate shortage list, which can differ.
| Presentation | Company | Status | Updated |
|---|---|---|---|
| Emend, Oral Powder for Suspension, 125 mg (NDC 0006-3066-03) | Merck Sharp & Dohme LLC | To Be Discontinued | April 8, 2026 |
Source: FDA Drug Shortage Database via openFDA, updated October 8, 2026
Has aprepitant been recalled?
The FDA's Enforcement Report lists 3 recalls naming aprepitant since 2018: 0 Class I (the most serious), 2 Class II, 1 Class III; 1 still ongoing. A recall names products and lots, not every product of the medicine.
| Started | Class | Company | Reason |
|---|---|---|---|
| December 12, 2025 | Class II | Merck Sharp & Dohme LLC | Presence of particulate matter: potential presence of metal particulates in the product. |
| April 13, 2022 | Class II | Mckesson Medical-Surgical Inc. Corporate Office | cGMP deviations: Temperature abuse |
| November 27, 2018 | Class III | Glenmark Pharmaceuticals Inc., USA | Shortfill: Aprepitant capsules 40 mg is being recalled due to customer reports of missing capsule in the blister pack. |
Source: FDA Enforcement Report (drug recalls) via openFDA, through October 8, 2026
What does the aprepitant label say about other medicines?
The aprepitant label names 27 other medicines in its interaction, contraindication or warning sections. The labels of 22 other medicines name aprepitant. The sentences are the labels' own; a label lists what its studies and reports found, not every interaction.
| Medicine named | Section | What the label says |
|---|---|---|
| Alprazolam | drug interactions | Clinical Impact; Increased exposure to midazolam or other benzodiazepines metabolized via CYP3A4 (alprazolam, triazolam) may increase the risk of adverse reactions [see ]. |
| Carbamazepine | drug interactions | Examples; rifampin, carbamazepine, phenytoin |
| Clarithromycin | drug interactions | Examples; Moderate inhibitor: diltiazem Strong inhibitors: ketoconazole, itraconazole, nefazodone, troleandomycin, clarithromycin, ritonavir, nelfinavir |
| Dexamethasone | drug interactions | Clinical Impact; Increased dexamethasone exposure [see ]. |
| Diltiazem | drug interactions | Examples; Moderate inhibitor: diltiazem Strong inhibitors: ketoconazole, itraconazole, nefazodone, troleandomycin, clarithromycin, ritonavir, nelfinavir |
| Docetaxel | drug interactions | Etoposide, vinorelbine, paclitaxel, and docetaxel No dosage adjustment needed. |
| Etoposide | drug interactions | Etoposide, vinorelbine, paclitaxel, and docetaxel No dosage adjustment needed. |
| Fosaprepitant | contraindications | CONTRAINDICATIONS EMEND is contraindicated in patients: who are hypersensitive to any component of the product. |
| Granisetron | drug interactions | Examples; ondansetron, granisetron, dolasetron |
| Ifosfamide | drug interactions | Intervention; Vinblastine, vincristine, or ifosfamide or other chemotherapeutic agents Monitor for chemotherapeutic-related adverse reactions. Etoposide, vinorelbine, paclitaxel, and docetaxel No dosage adjustment needed. |
| Itraconazole | drug interactions | Examples; Moderate inhibitor: diltiazem Strong inhibitors: ketoconazole, itraconazole, nefazodone, troleandomycin, clarithromycin, ritonavir, nelfinavir |
| Ketoconazole | drug interactions | Examples; Moderate inhibitor: diltiazem Strong inhibitors: ketoconazole, itraconazole, nefazodone, troleandomycin, clarithromycin, ritonavir, nelfinavir |
| Methylprednisolone | drug interactions | Methylprednisolone Clinical Impact Increased methylprednisolone exposure [see Clinical Pharmacology (12.3) ]. |
| Midazolam | drug interactions | Clinical Impact; Increased exposure to midazolam or other benzodiazepines metabolized via CYP3A4 (alprazolam, triazolam) may increase the risk of adverse reactions [see ]. |
Every other medicine the aprepitant label names
| Medicine named | Section | What the label says |
|---|---|---|
| Nefazodone | drug interactions | Examples; Moderate inhibitor: diltiazem Strong inhibitors: ketoconazole, itraconazole, nefazodone, troleandomycin, clarithromycin, ritonavir, nelfinavir |
| Nelfinavir | drug interactions | Examples; Moderate inhibitor: diltiazem Strong inhibitors: ketoconazole, itraconazole, nefazodone, troleandomycin, clarithromycin, ritonavir, nelfinavir |
| Ondansetron | drug interactions | Examples; ondansetron, granisetron, dolasetron |
| Paclitaxel | drug interactions | Etoposide, vinorelbine, paclitaxel, and docetaxel No dosage adjustment needed. |
| Phenytoin | drug interactions | Examples; rifampin, carbamazepine, phenytoin |
| Pimozide | contraindications | … life-threatening reactions, such as QT prolongation, a known adverse reaction of pimozide [see Warnings and Precautions (5.1) ]. |
| Rifampin | drug interactions | Examples; rifampin, carbamazepine, phenytoin |
| Ritonavir | drug interactions | Examples; Moderate inhibitor: diltiazem Strong inhibitors: ketoconazole, itraconazole, nefazodone, troleandomycin, clarithromycin, ritonavir, nelfinavir |
| Triazolam | drug interactions | Clinical Impact; Increased exposure to midazolam or other benzodiazepines metabolized via CYP3A4 (alprazolam, triazolam) may increase the risk of adverse reactions [see ]. |
| Vinblastine | drug interactions | Intervention; Vinblastine, vincristine, or ifosfamide or other chemotherapeutic agents Monitor for chemotherapeutic-related adverse reactions. … |
| Vincristine | drug interactions | Intervention; Vinblastine, vincristine, or ifosfamide or other chemotherapeutic agents Monitor for chemotherapeutic-related adverse reactions. … |
| Vinorelbine | drug interactions | Etoposide, vinorelbine, paclitaxel, and docetaxel No dosage adjustment needed. |
| Warfarin | drug interactions | Clinical Impact; Decreased warfarin exposure and decreased prothrombin time (INR) [see, ]. |
Other labels that name aprepitant
Source: FDA drug label (EMEND), NDA021549 (Msd), as published by Merck Sharp & Dohme LLC, effective July 5, 2024 (SPL set 696f9e80-9cae-403b-de9e-078343ce4713), via openFDA; the full label on DailyMed
What do FAERS reports show for aprepitant?
The FDA Adverse Event Reporting System holds 18,353 reports that list aprepitant among the medicines taken, through July 30, 2026, each a report of something that happened, not proof the medicine caused it; 3,080 are coded as a death and 10,066 as a hospital stay. Counts follow how widely a medicine is used and watched, and they are not a measure of how risky it is.
Reports received each year
The most reported reactions
Source: FDA Adverse Event Reporting System (FAERS) via openFDA, reports through July 30, 2026
What else is labeled for the same conditions as aprepitant?
7 other medicines are given the same way (oral) and in the same FDA class as aprepitant or labeled mainly for the same use (nausea and vomiting), the same class first. Nausea and vomiting lists all 16 medicines labeled for it, by any route. They are listed as records, not as substitutes: whether one can replace another is a prescriber's decision.
| Medicine | Shared indication | Generic labelers (oral) | Pharmacy cost | Shortage |
|---|---|---|---|---|
| Ondansetron | Nausea and vomiting | 60 labelers | $0.0582 per tablet 4 mg tablet | No current entry |
| Meclizine | Nausea and vomiting | 24 labelers | $0.0442 per tablet 12.5 mg tablet | No current entry |
| Prochlorperazine | Nausea and vomiting | 29 labelers | $0.162 per tablet 10 mg tablet | No current entry |
| Dimenhydrinate | Nausea and vomiting | none listed | $0.0575 per tablet 50 mg tablet | No current entry |
| Doxylamine and pyridoxine | Nausea and vomiting | 4 labelers | $1.09 per unit 10-10 mg | No current entry |
| Trimethobenzamide | Nausea and vomiting | 4 labelers | n/a | No current entry |
| Tradipitant | Nausea and vomiting | none listed | n/a | No current entry |
Every medicine labeled for the same conditions as aprepitant
Source: FDA drug labels (indications), NDC Directory, NADAC of October 7, 2026, FDA shortages (October 8, 2026)
How does aprepitant compare with medicines for the same use?
1 side-by-side page set aprepitant beside a medicine whose label shares a use: approvals, generics, pharmacy cost, warnings and supply.
What next?
- Alternatives to aprepitant
- 7 medicines for the same use
- Other substance p/neurokinin-1 receptor antagonists
- the pharmacologic class, with prices and generics
- Aprepitant side effects
- the label's list beside FAERS reports
- Aprepitant shortage record
- every presentation, company and date
- Check an interaction
- what two or more labels say about each other